title: Screening and treatment for Staphylococcus aureus in patients undergoing hemodialysis: a systematic review and meta-analysis.
abstract: BACKGROUND
  This study was performed to evaluate the effectiveness of surveillance for screening and treatment of patients with chronic kidney disease undergoing hemodialysis and colonized by Staphylococcus aureus.
  
  
  METHODS
  A systematic review and meta-analysis were performed. The literature search involved the following databases: the Cochrane Controlled Trials Register, Embase, LILACS, CINAHL, SciELO, and PubMed/Medline. The descriptors were "Staphylococcus aureus", "MRSA", "MSSA", "treatment", "decolonization", "nasal carrier", "colonization", "chronic kidney disease", "dialysis", and "haemodialysis" or "hemodialysis". Five randomized controlled trials that exhibited agreement among reviewers as shown by a kappa value of >0.80 were included in the study; methodological quality was evaluated using the STROBE statement. Patients who received various treatments (various treatments group) or topical mupirocin (mupirocin group) were compared with those who received either no treatment or placebo (control group). The outcomes were skin infection at the central venous catheter insertion site and bacteremia.
  
  
  RESULTS
  In total, 2374 patients were included in the analysis, 626 (26.4%) of whom were nasal carriers of S. aureus. The probability of S. aureus infection at the catheter site for hemodialysis was 87% lower in the mupirocin group than in the control group (odds ratio [OR], 0.13; 95% confidence interval [CI], 0.05-0.34; p<0.001). The risk of bacteremia was 82% lower in the mupirocin group than in the control group (OR, 0.18; 95% CI, 0.08-0.42; p<0.001). No statistically significant difference in bacteremia was observed between the various treatments group (excluding mupirocin) and the control group (OR, 0.77; 95% CI, 0.51-1.15; p=0.20).
  
  
  CONCLUSIONS
  Twenty-six percent of patients undergoing hemodialysis were nasal carriers of S. aureus. Of all treatments evaluated, topical mupirocin was the most effective therapy for the reduction of S. aureus catheter site infection and bacteremia in patients undergoing chronic hemodialysis.
authors.affiliation: Paulista School of Nursing, Universidade Federal de São Paulo (Federal University of São Paulo - EPE/UNIFESP), R, Napoleão de Barros 754, São Paulo 04024-002, Brazil. cibelegrothe@hotmail.com.
authors.forename: Cibele
authors.initials: C
authors.lastname: Grothe
authors.forename: Mônica
authors.initials: M
authors.lastname: Taminato
authors.forename: Angélica
authors.initials: A
authors.lastname: Belasco
authors.forename: Ricardo
authors.initials: R
authors.lastname: Sesso
authors.forename: Dulce
authors.initials: D
authors.lastname: Barbosa
mesh_terms: D000287:Administration, Topical; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D016470:Bacteremia / Q000175:diagnosis / Q000517:prevention & control; D002353:Carrier State / Q000175:diagnosis / Q000517:prevention & control; D055499:Catheter-Related Infections / Q000175:diagnosis* / Q000517:prevention & control*; D002405:Catheterization, Central Venous / Q000009:adverse effects; D006801:Humans; D016712:Mupirocin / Q000008:administration & dosage; D006435:Renal Dialysis / Q000009:adverse effects*; D051436:Renal Insufficiency, Chronic / Q000628:therapy; D013203:Staphylococcal Infections / Q000175:diagnosis* / Q000517:prevention & control*; D013207:Staphylococcal Skin Infections / Q000175:diagnosis / Q000517:prevention & control
chemical_list: D000900:Anti-Bacterial Agents; D016712:Mupirocin